JP7475811B2 - 遺伝子に基づく炎症性腸疾患の診断 - Google Patents
遺伝子に基づく炎症性腸疾患の診断 Download PDFInfo
- Publication number
- JP7475811B2 JP7475811B2 JP2018560186A JP2018560186A JP7475811B2 JP 7475811 B2 JP7475811 B2 JP 7475811B2 JP 2018560186 A JP2018560186 A JP 2018560186A JP 2018560186 A JP2018560186 A JP 2018560186A JP 7475811 B2 JP7475811 B2 JP 7475811B2
- Authority
- JP
- Japan
- Prior art keywords
- allele
- pos
- snp
- nuclear
- ibd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000022559 Inflammatory bowel disease Diseases 0.000 title claims description 171
- 108090000623 proteins and genes Proteins 0.000 title description 165
- 238000003745 diagnosis Methods 0.000 title description 3
- 108700028369 Alleles Proteins 0.000 claims description 257
- 238000000034 method Methods 0.000 claims description 100
- 239000000523 sample Substances 0.000 claims description 47
- 238000011282 treatment Methods 0.000 claims description 38
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims description 36
- 239000002751 oligonucleotide probe Substances 0.000 claims description 36
- 238000003205 genotyping method Methods 0.000 claims description 31
- 238000009396 hybridization Methods 0.000 claims description 31
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 21
- 208000011231 Crohn disease Diseases 0.000 claims description 21
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 21
- 238000002493 microarray Methods 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 18
- 239000002773 nucleotide Substances 0.000 claims description 15
- 125000003729 nucleotide group Chemical group 0.000 claims description 15
- 238000003556 assay Methods 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 8
- 210000000349 chromosome Anatomy 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 6
- 238000003752 polymerase chain reaction Methods 0.000 claims description 6
- 230000027455 binding Effects 0.000 claims description 5
- 238000001712 DNA sequencing Methods 0.000 claims description 2
- 238000003559 RNA-seq method Methods 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 238000003753 real-time PCR Methods 0.000 claims description 2
- 238000003757 reverse transcription PCR Methods 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 72
- 201000010099 disease Diseases 0.000 description 66
- 238000001514 detection method Methods 0.000 description 43
- 102100029877 F-actin-uncapping protein LRRC16A Human genes 0.000 description 36
- 101000793823 Homo sapiens F-actin-uncapping protein LRRC16A Proteins 0.000 description 36
- 230000002068 genetic effect Effects 0.000 description 32
- 108010033040 Histones Proteins 0.000 description 29
- 239000003795 chemical substances by application Substances 0.000 description 28
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 26
- 102000013698 Cyclin-Dependent Kinase 6 Human genes 0.000 description 26
- 101000876829 Homo sapiens Protein C-ets-1 Proteins 0.000 description 26
- 102100035251 Protein C-ets-1 Human genes 0.000 description 26
- 238000004458 analytical method Methods 0.000 description 25
- 102000054766 genetic haplotypes Human genes 0.000 description 23
- 101000653374 Homo sapiens Methylcytosine dioxygenase TET2 Proteins 0.000 description 18
- 102100030803 Methylcytosine dioxygenase TET2 Human genes 0.000 description 18
- 108020004707 nucleic acids Proteins 0.000 description 18
- 102000039446 nucleic acids Human genes 0.000 description 18
- 150000007523 nucleic acids Chemical class 0.000 description 18
- 238000002560 therapeutic procedure Methods 0.000 description 18
- 239000000975 dye Substances 0.000 description 16
- 238000012100 gene-based analysis Methods 0.000 description 14
- 238000012360 testing method Methods 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- 241000218645 Cedrus Species 0.000 description 10
- 102100039997 Gastric inhibitory polypeptide receptor Human genes 0.000 description 10
- 102100037475 General transcription factor II-I repeat domain-containing protein 2B Human genes 0.000 description 10
- 101000902096 Homo sapiens Disks large homolog 4 Proteins 0.000 description 10
- 101000886866 Homo sapiens Gastric inhibitory polypeptide receptor Proteins 0.000 description 10
- 101001026144 Homo sapiens General transcription factor II-I repeat domain-containing protein 2B Proteins 0.000 description 10
- 101001047515 Homo sapiens Lethal(2) giant larvae protein homolog 1 Proteins 0.000 description 10
- 101001090551 Homo sapiens Proline-rich protein 5-like Proteins 0.000 description 10
- 101000804728 Homo sapiens Protein Wnt-2b Proteins 0.000 description 10
- 101000611192 Homo sapiens Trinucleotide repeat-containing gene 6B protein Proteins 0.000 description 10
- 101000788658 Homo sapiens Zinc fingers and homeoboxes protein 3 Proteins 0.000 description 10
- 102100022956 Lethal(2) giant larvae protein homolog 1 Human genes 0.000 description 10
- 102100035278 Pendrin Human genes 0.000 description 10
- 102100034734 Proline-rich protein 5-like Human genes 0.000 description 10
- 102100035289 Protein Wnt-2b Human genes 0.000 description 10
- 108091006507 SLC26A4 Proteins 0.000 description 10
- 108091006277 SLC5A1 Proteins 0.000 description 10
- 102000058090 Sodium-Glucose Transporter 1 Human genes 0.000 description 10
- 102100040244 Trinucleotide repeat-containing gene 6B protein Human genes 0.000 description 10
- 102100025095 Zinc fingers and homeoboxes protein 3 Human genes 0.000 description 10
- 230000009466 transformation Effects 0.000 description 10
- 102100027138 Butyrophilin subfamily 3 member A1 Human genes 0.000 description 9
- 101000984934 Homo sapiens Butyrophilin subfamily 3 member A1 Proteins 0.000 description 9
- 108091034117 Oligonucleotide Proteins 0.000 description 9
- 230000000670 limiting effect Effects 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 230000000968 intestinal effect Effects 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 238000012408 PCR amplification Methods 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- 230000002596 correlated effect Effects 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000012321 colectomy Methods 0.000 description 6
- 206010009887 colitis Diseases 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 239000007850 fluorescent dye Substances 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 102100027155 Butyrophilin subfamily 3 member A2 Human genes 0.000 description 5
- 101000984917 Homo sapiens Butyrophilin subfamily 3 member A2 Proteins 0.000 description 5
- 101100480850 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) TDA3 gene Proteins 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 238000010197 meta-analysis Methods 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 239000005022 packaging material Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000004761 fibrosis Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000013507 mapping Methods 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 102100025971 F-actin-capping protein subunit alpha-2 Human genes 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 101000933166 Homo sapiens F-actin-capping protein subunit alpha-2 Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 210000003097 mucus Anatomy 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 238000013488 ordinary least square regression Methods 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 108091023037 Aptamer Proteins 0.000 description 2
- 241000282421 Canidae Species 0.000 description 2
- 238000000018 DNA microarray Methods 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 101001024425 Mus musculus Ig gamma-2A chain C region secreted form Proteins 0.000 description 2
- 241000282579 Pan Species 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000033289 adaptive immune response Effects 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000001364 causal effect Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 101150090724 3 gene Proteins 0.000 description 1
- 241000282672 Ateles sp. Species 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 241000157302 Bison bison athabascae Species 0.000 description 1
- 102100027154 Butyrophilin subfamily 3 member A3 Human genes 0.000 description 1
- 108010017533 Butyrophilins Proteins 0.000 description 1
- 102000004555 Butyrophilins Human genes 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 102100029875 Capping protein, Arp2/3 and myosin-I linker protein 3 Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 230000035131 DNA demethylation Effects 0.000 description 1
- 239000012626 DNA minor groove binder Substances 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 102100027581 Forkhead box protein P3 Human genes 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- 102100022653 Histone H1.5 Human genes 0.000 description 1
- 102100034523 Histone H4 Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000984916 Homo sapiens Butyrophilin subfamily 3 member A3 Proteins 0.000 description 1
- 101000793839 Homo sapiens Capping protein, Arp2/3 and myosin-I linker protein 3 Proteins 0.000 description 1
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 description 1
- 101000899879 Homo sapiens Histone H1.5 Proteins 0.000 description 1
- 101001067880 Homo sapiens Histone H4 Proteins 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 101000853012 Homo sapiens Interleukin-23 receptor Proteins 0.000 description 1
- 101001125026 Homo sapiens Nucleotide-binding oligomerization domain-containing protein 2 Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102100036672 Interleukin-23 receptor Human genes 0.000 description 1
- 206010072877 Intestinal fibrosis Diseases 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 238000007476 Maximum Likelihood Methods 0.000 description 1
- 108030004080 Methylcytosine dioxygenases Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 description 1
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 102100029441 Nucleotide-binding oligomerization domain-containing protein 2 Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 201000001509 acute urate nephropathy Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- -1 antibodies Proteins 0.000 description 1
- 238000012093 association test Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 238000003936 denaturing gel electrophoresis Methods 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000016379 mucosal immune response Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000001243 pseudopodia Anatomy 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 208000019808 uric acid nephrolithiasis Diseases 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Medical Informatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022044738A JP7392020B2 (ja) | 2016-05-20 | 2022-03-18 | 遺伝子に基づく炎症性腸疾患の診断 |
| JP2023213224A JP2024037945A (ja) | 2016-05-20 | 2023-12-18 | 遺伝子に基づく炎症性腸疾患の診断 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662339357P | 2016-05-20 | 2016-05-20 | |
| US62/339,357 | 2016-05-20 | ||
| PCT/US2017/033625 WO2017201461A1 (en) | 2016-05-20 | 2017-05-19 | Diagnosis of inflammatory bowel disease based on genes |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022044738A Division JP7392020B2 (ja) | 2016-05-20 | 2022-03-18 | 遺伝子に基づく炎症性腸疾患の診断 |
| JP2023213224A Division JP2024037945A (ja) | 2016-05-20 | 2023-12-18 | 遺伝子に基づく炎症性腸疾患の診断 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019516375A JP2019516375A (ja) | 2019-06-20 |
| JP2019516375A5 JP2019516375A5 (enExample) | 2020-06-18 |
| JP7475811B2 true JP7475811B2 (ja) | 2024-04-30 |
Family
ID=60326226
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018560186A Active JP7475811B2 (ja) | 2016-05-20 | 2017-05-19 | 遺伝子に基づく炎症性腸疾患の診断 |
| JP2022044738A Active JP7392020B2 (ja) | 2016-05-20 | 2022-03-18 | 遺伝子に基づく炎症性腸疾患の診断 |
| JP2023213224A Pending JP2024037945A (ja) | 2016-05-20 | 2023-12-18 | 遺伝子に基づく炎症性腸疾患の診断 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022044738A Active JP7392020B2 (ja) | 2016-05-20 | 2022-03-18 | 遺伝子に基づく炎症性腸疾患の診断 |
| JP2023213224A Pending JP2024037945A (ja) | 2016-05-20 | 2023-12-18 | 遺伝子に基づく炎症性腸疾患の診断 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11549146B2 (enExample) |
| EP (1) | EP3458466B1 (enExample) |
| JP (3) | JP7475811B2 (enExample) |
| KR (4) | KR20190016972A (enExample) |
| CN (2) | CN117286238A (enExample) |
| WO (1) | WO2017201461A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010062960A2 (en) | 2008-11-26 | 2010-06-03 | Cedars-Sinai Medical Center | METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE |
| KR20240095481A (ko) | 2016-03-17 | 2024-06-25 | 세다르스-신나이 메디칼 센터 | Rnaset2를 통한 염증성 장 질환의 진단 방법 |
| EP3458466B1 (en) | 2016-05-20 | 2024-08-07 | Cedars-Sinai Medical Center | Diagnosis of inflammatory bowel disease based on genes |
| KR20220088529A (ko) | 2019-05-14 | 2022-06-27 | 프로메테우스 바이오사이언시즈, 인크. | Tl1a 환자 선택 방법, 시스템 및 장치 |
| JP2022022994A (ja) * | 2020-06-26 | 2022-02-07 | ファイザー・インク | Ｔｌ１ａ抗体で炎症性腸疾患を処置する方法 |
| JP2023551602A (ja) * | 2020-11-13 | 2023-12-08 | プロメテウス バイオサイエンシーズ，インク． | Ｔｌ１ａを標的とする炎症性疾患の治療のための方法、システム、およびキット |
| CN115851911B (zh) * | 2022-11-25 | 2025-10-24 | 南京鼓楼医院 | 一种用于鉴别狼疮性肾炎的尿液外泌体tsRNA标志物和探针及其应用 |
| EP4646434A2 (en) * | 2023-01-06 | 2025-11-12 | Prometheus Biosciences, Inc. | Methods of treating inflammatory diseases with combination of tl1a inhibitors and tnf inhibitors |
| WO2025038473A1 (en) | 2023-08-11 | 2025-02-20 | Paragon Therapeutics, Inc. | Tl1a binding antibodies and methods of use |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008106451A2 (en) | 2007-02-26 | 2008-09-04 | Cedars-Sinai Medical Center | Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease |
| WO2010062960A2 (en) | 2008-11-26 | 2010-06-03 | Cedars-Sinai Medical Center | METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE |
| WO2014186750A2 (en) | 2013-05-17 | 2014-11-20 | Cedars-Sinai Medical Center | Variants of tnfsf15 and dcr3 associated with crohn's disease |
| JP2015502740A (ja) | 2011-10-21 | 2015-01-29 | ネステク ソシエテ アノニム | 炎症性腸疾患の診断を改善するための方法 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4443421A (en) | 1982-03-16 | 1984-04-17 | Occidental Chemical Corporation | Process for removing particulate impurities from aqueous phosphoric acid |
| US4707260A (en) | 1984-08-27 | 1987-11-17 | Toray Industries, Inc. | Solid liquid separation device |
| US5000850A (en) | 1986-09-10 | 1991-03-19 | Engelhard Corporation | Apparatus for dewatering an aqueous clay suspension |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US7357927B2 (en) | 1996-03-12 | 2008-04-15 | Human Genome Sciences, Inc. | Death domain containing receptors |
| EP1100962A1 (en) | 1998-07-25 | 2001-05-23 | AstraZeneca AB | Genetic polymorphisms in the human neurokinin 1 receptor gene and their uses in diagnosis and treatment of diseases |
| JP2004194534A (ja) | 2002-12-17 | 2004-07-15 | Sumitomo Pharmaceut Co Ltd | 炎症性腸疾患疾患マーカーおよびその利用 |
| PT1673473E (pt) * | 2003-10-06 | 2011-09-19 | Novartis Ag | Utilização de polimorfismos genéticos associados à eficácia do tratamento de doenças inflamatórias |
| US20060134663A1 (en) | 2004-11-03 | 2006-06-22 | Paul Harkin | Transcriptome microarray technology and methods of using the same |
| KR101443050B1 (ko) | 2005-05-06 | 2014-09-22 | 지모제넥틱스, 인코포레이티드 | Ｉｌ-31 단클론성 항체 및 사용법 |
| WO2006127900A2 (en) | 2005-05-25 | 2006-11-30 | Biogen Idec Ma Inc. | Tl1a in the treatment of disease |
| EP1963534A2 (en) * | 2005-12-19 | 2008-09-03 | Genizon Biosciences Inc. | Genemap of the human gene associated with crohn's disease |
| US20090018031A1 (en) | 2006-12-07 | 2009-01-15 | Switchgear Genomics | Transcriptional regulatory elements of biological pathways tools, and methods |
| US20110217310A1 (en) * | 2007-01-10 | 2011-09-08 | Siegel Richard M | Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology |
| US20080221056A1 (en) * | 2007-02-12 | 2008-09-11 | Johns Hopkins University | Early Detection and Prognosis of Colon Cancers |
| US20100055700A1 (en) | 2007-02-28 | 2010-03-04 | Cedars-Sinai Medical Center | Role of il-12, il-23 and il-17 receptors in inflammatory bowel disease |
| US20150376707A1 (en) | 2007-05-18 | 2015-12-31 | Cedars-Sinai Medical Center | Methods of diagnosing and treating inflammatory bowel disease |
| US8118175B2 (en) | 2007-07-18 | 2012-02-21 | Siemens Industry, Inc. | Venting device for a disc filter |
| WO2009039244A2 (en) * | 2007-09-18 | 2009-03-26 | Genizon Biosciences Inc. | Genemap of the human genes associated with crohn's disease |
| US20100240043A1 (en) * | 2007-10-19 | 2010-09-23 | Cedars-Sinai Medical Center | Methods of using genetic variants to diagnose and predict inflammatory bowel disease |
| EP2220122A2 (en) | 2007-11-13 | 2010-08-25 | Teva Biopharmaceuticals USA, Inc. | Humanized antibodies against tl1a |
| PT2324126E (pt) | 2008-08-12 | 2014-06-02 | Zinfandel Pharmaceuticals Inc | Método de identificação de factores de risco da doença de alzheimer |
| DK2329259T3 (en) | 2008-08-29 | 2016-05-09 | Janssen Biotech Inc | MARKERS AND PROCEDURES FOR ASSESSING AND TREATING ULCERATIVE COLITIS AND RELATED DISEASES USING A 20-GEN PANEL |
| JP2010088432A (ja) | 2008-09-09 | 2010-04-22 | Kansetsu Saisei Kenkyusho:Kk | Ｔｎｆ阻害薬治療による有効性・副作用発現に関する多型、およびその利用 |
| WO2010075579A2 (en) | 2008-12-24 | 2010-07-01 | Cedars-Sinai Medical Center | Methods of predicting medically refractive ulcerative colitis (mr-uc) requiring colectomy |
| EP2419529B1 (en) | 2009-04-14 | 2015-05-20 | Nestec S.A. | Inflammatory bowel disease prognostics |
| US20130136720A1 (en) | 2010-01-15 | 2013-05-30 | Cedars-Sinai Medical Center | Methods of using fut2 genetic variants to diagnose crohn's disease |
| CA2801575A1 (en) * | 2010-06-04 | 2011-12-08 | Prometheus Laboratories Inc. | Methods for improving inflammatory bowel disease diagnosis |
| US8766034B2 (en) | 2010-09-22 | 2014-07-01 | Cedars-Sinai Medical Center | TL1A model of inflammation fibrosis and autoimmunity |
| EP3702460A1 (en) | 2010-11-12 | 2020-09-02 | The General Hospital Corporation | Polycomb-associated non-coding rnas |
| US9902996B2 (en) | 2011-02-11 | 2018-02-27 | Cedars-Sinai Medical Center | Methods of predicting the need for surgery in crohn's disease |
| CN103649336A (zh) | 2011-05-10 | 2014-03-19 | 雀巢产品技术援助有限公司 | 用于个体化治疗管理的疾病活动性表征方法 |
| EP2710147A1 (en) | 2011-05-18 | 2014-03-26 | Rheinische Friedrich-Wilhelms-Universität Bonn | Molecular analysis of acute myeloid leukemia |
| JP2014518883A (ja) | 2011-05-20 | 2014-08-07 | ガバメント・オブ・ザ・ユナイテッド・ステイツ，アズ・リプリゼンテッド・バイ・ザ・セクレタリー，デパートメント・オブ・ヘルス・アンド・ヒューマン・サーヴィシズ | Ｔ細胞媒介疾病の病態を改善させるためのｔｌ１ａ−ｄｒ３相互作用の遮断及びその抗体 |
| EA201990698A1 (ru) | 2011-06-03 | 2019-12-30 | Ксома Текнолоджи Лтд. | Антитела, специфические к tgf-бета |
| CA2864133A1 (en) | 2012-02-10 | 2013-08-15 | Novo Nordisk A/S | Methods related to treatment of inflammatory diseases and disorders |
| KR20210157418A (ko) | 2013-03-27 | 2021-12-28 | 세다르스-신나이 메디칼 센터 | Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전 |
| BR112016007474A2 (pt) * | 2013-10-09 | 2017-09-12 | Cedars Sinai Medical Center | diagnóstico e tratamento de síndrome do intestino irritável e doença inflamatória intestinal |
| US11365447B2 (en) * | 2014-03-13 | 2022-06-21 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| EP3286318A2 (en) | 2015-04-22 | 2018-02-28 | Mina Therapeutics Limited | Sarna compositions and methods of use |
| KR102629266B1 (ko) | 2016-02-26 | 2024-01-24 | 나노테크 에너지, 인크. | 탄소질 조성물의 프로세싱을 위한 방법, 디바이스 및 시스템 |
| EP3458466B1 (en) * | 2016-05-20 | 2024-08-07 | Cedars-Sinai Medical Center | Diagnosis of inflammatory bowel disease based on genes |
| WO2018022982A1 (en) | 2016-07-29 | 2018-02-01 | Trustees Of Boston University | Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development |
| EP3532489A4 (en) | 2016-10-26 | 2020-07-08 | Cedars-Sinai Medical Center | ANTI-TL1A NEUTRALIZING MONOCLONAL ANTIBODIES |
| WO2018204764A1 (en) | 2017-05-05 | 2018-11-08 | Camp4 Therapeutics Corporation | Identification and targeted modulation of gene signaling networks |
| US11675142B2 (en) | 2018-12-14 | 2023-06-13 | Fujikura Ltd. | Ferrule, fiber-equipped ferrule, and method for manufacturing fiber-equipped ferrule |
-
2017
- 2017-05-19 EP EP17800279.6A patent/EP3458466B1/en active Active
- 2017-05-19 CN CN202311263442.0A patent/CN117286238A/zh active Pending
- 2017-05-19 CN CN201780044934.7A patent/CN109476698B/zh active Active
- 2017-05-19 KR KR1020187037151A patent/KR20190016972A/ko not_active Ceased
- 2017-05-19 KR KR1020247019512A patent/KR20240095363A/ko not_active Ceased
- 2017-05-19 US US16/303,033 patent/US11549146B2/en active Active
- 2017-05-19 KR KR1020227044940A patent/KR20230003433A/ko not_active Ceased
- 2017-05-19 JP JP2018560186A patent/JP7475811B2/ja active Active
- 2017-05-19 WO PCT/US2017/033625 patent/WO2017201461A1/en not_active Ceased
- 2017-05-19 KR KR1020227003985A patent/KR102481305B1/ko active Active
-
2022
- 2022-03-18 JP JP2022044738A patent/JP7392020B2/ja active Active
- 2022-12-09 US US18/063,931 patent/US20230366028A1/en active Pending
-
2023
- 2023-12-18 JP JP2023213224A patent/JP2024037945A/ja active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008106451A2 (en) | 2007-02-26 | 2008-09-04 | Cedars-Sinai Medical Center | Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease |
| WO2010062960A2 (en) | 2008-11-26 | 2010-06-03 | Cedars-Sinai Medical Center | METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE |
| JP2015502740A (ja) | 2011-10-21 | 2015-01-29 | ネステク ソシエテ アノニム | 炎症性腸疾患の診断を改善するための方法 |
| WO2014186750A2 (en) | 2013-05-17 | 2014-11-20 | Cedars-Sinai Medical Center | Variants of tnfsf15 and dcr3 associated with crohn's disease |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017201461A1 (en) | 2017-11-23 |
| JP7392020B2 (ja) | 2023-12-05 |
| JP2019516375A (ja) | 2019-06-20 |
| KR20220025122A (ko) | 2022-03-03 |
| EP3458466A4 (en) | 2020-03-04 |
| US11549146B2 (en) | 2023-01-10 |
| CN109476698B (zh) | 2023-10-17 |
| KR102481305B1 (ko) | 2022-12-26 |
| EP3458466A1 (en) | 2019-03-27 |
| KR20230003433A (ko) | 2023-01-05 |
| JP2022095688A (ja) | 2022-06-28 |
| JP2024037945A (ja) | 2024-03-19 |
| US20230366028A1 (en) | 2023-11-16 |
| CN117286238A (zh) | 2023-12-26 |
| US20190194754A1 (en) | 2019-06-27 |
| CN109476698A (zh) | 2019-03-15 |
| EP3458466B1 (en) | 2024-08-07 |
| KR20190016972A (ko) | 2019-02-19 |
| KR20240095363A (ko) | 2024-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7392020B2 (ja) | 遺伝子に基づく炎症性腸疾患の診断 | |
| EP2689036B1 (en) | Methods of diagnosing and treating intestinal granulomas and low bone density in inflammatory bowel disease | |
| US20100055700A1 (en) | Role of il-12, il-23 and il-17 receptors in inflammatory bowel disease | |
| US20100144903A1 (en) | Methods of diagnosis and treatment of crohn's disease | |
| US20110177969A1 (en) | The role of il17rd and the il23-1l17 pathway in crohn's disease | |
| US20100184050A1 (en) | Diagnosis and treatment of inflammatory bowel disease in the puerto rican population | |
| MX2008016524A (es) | Biomarcadores para la progresion de la enfermedad de alzheimer. | |
| WO2008144316A1 (en) | Blood biomarkers for psychosis | |
| US9305137B1 (en) | Methods of identifying the genetic basis of a disease by a combinatorial genomics approach, biological pathway approach, and sequential approach | |
| US20180208988A1 (en) | Methods of diagnosis and treatment of inflammatory bowel disease | |
| US20200102610A1 (en) | Method for cerebral palsy prediction | |
| JP2020089370A (ja) | 抗精神病薬に基づく処置により誘導される錐体外路症状（ｅｐｓ）の発症を予測する方法 | |
| CA2946317A1 (en) | Methods of predicting medically refractive ulcerative colitis (mruc) requiring colectomy | |
| JP2006518206A (ja) | 処置中の自殺傾向を予測するための方法 | |
| US20120190698A1 (en) | Methods of predicting thiopurine response | |
| US20120041082A1 (en) | Methods of using smad3 and jak2 genetic variants to diagnose and predict inflammatory bowel disease | |
| CN119220666A (zh) | Chrm3基因多态性在阿托品易感近视人群诊断或筛查中的应用 | |
| AU2005250142B2 (en) | Biomarkers for the prediction of responsiveness to clozapine treatment | |
| US20170240965A1 (en) | Methods for prognosing heart transplant | |
| WO2025189251A1 (en) | Diagnostic and prognostic signatures for sepsis | |
| Aus Kermanshah | Masoud Garshasbi |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190122 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200507 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200508 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210506 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210805 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210806 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20211122 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220318 |
|
| C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20220318 |
|
| C11 | Written invitation by the commissioner to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C11 Effective date: 20220404 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20220506 |
|
| C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20220509 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20220527 |
|
| C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20220601 |
|
| RD12 | Notification of acceptance of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7432 Effective date: 20230428 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20230428 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231218 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20240116 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20240116 |
|
| RD14 | Notification of resignation of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7434 Effective date: 20240116 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240417 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7475811 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |